Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

Kidney (Renal Cell)

This clinical trial is a randomized Phase 2 evaluation of CB-839 (telaglenastat) in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic Renal Cell Carcinoma with a clear cell component.
Kidney (Renal Cell)
II
Davis, Nancy
NCT03428217
VICCURO1835

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: